LNAILunai Bioworks Inc.
LNAI
Lunai Bioworks Inc.3,807
Mkt Cap
$9.57MVolume
145,826.0052W High
$35.9752W Low
$1.21PE Ratio
-0.03LNAI Fundamentals
Price
$2.64Prev Close
$2.11Open
$2.1050D MA
$2.74Beta
1.39Avg. Volume
1.39MEPS (Annual)
-$86.27P/B
-0.99Rev/Employee
$0.00$57.65
Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock
Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock PR Newswire WASHINGTON, May 22, 2026 WASHINGTON, May 22, 2026...
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT PR Newswire SACRAMENTO, Calif., May 20, 2026 SACRAMENTO, Calif., May 20, 2026 /PRNewswire/ --Lunai Bioworks, Inc. (Nasdaq: LNAI) (the "Company") today announced that it will effect a reverse stock...
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and...
Stock Market Today: Dow Jones, S&P 500 Futures Edge Lower Amid Extension Of Israel-Lebanon Ceasefire Intel, SAP, Lunai Bioworks In Focus
U.S. stock futures were mixed on Friday following Thursday's decline, after President Donald Trump announced the extension of the ceasefire between Israel and Lebanon by three weeks. On Thursday, the...
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient...
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under...
AI, Biotech, and Defense Converge: Small Caps Chase Big Markets as Innovation Narrative Heats Up
Today's top stocks include $LNAI, $HCTI, $TGNT, $KOD, $NAVN, $BTBD
Lunai Bioworks Unveils AI-Driven National Consortium to Fast-Track Chemical Defense Countermeasures
Lunai Bioworks (NASDAQ:LNAI) launched a new national consortium aimed at transforming how the United States develops medical countermeasures against emerging chemical threats. Operating through its subsidiary BioSymetrics, the company introduced the Pathfinder Consortium, an academic-industry alliance designed to unify historically fragmented chemical defense efforts across government, academia, and biotech into a single, execution-focused platform.
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS...
<
1
2
...
>
Compact View
Not available
Not available